Results 61 to 70 of about 5,421 (159)

In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam

Open Forum Infectious Diseases, 2023
Abstract The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam ...
Mollie VanNatta, Laurie Grier, Muhammad H Khan, Paulette Pinargote Cornejo, Mohammad Alam, Samir H Moussa, Jennifer G Smith, Samuel L Aitken, Alexandre E Malek   +8 more
openaire   +2 more sources

Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 6, Page 386-392, June 2025.
Abstract Introduction Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β‐lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.
Jay D. Olivet, Megan Amerson‐Brown, Juan J. Calix, Emma Graffice, Tyson Kilpatrick, Hanna F. Roenfanz, David P. Nicolau, Joseph L. Kuti, Matthew L. Brown   +8 more
wiley   +1 more source

Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants

Antimicrobial Agents and Chemotherapy
The persistence of multidrug-resistant Acinetobacter baumannii remains a clinical challenge. Cefepime/enmetazobactam is a novel combination with demonstrated activity against extended-spectrum β-lactamase-producing Enterobacterales, but its activity ...
Gabriela-Alejandra Báez-Barroso, Arianna Rodríguez-Coello, Juan Carlos Vázquez-Ucha, Silvia López-Argüello, Michelle Outeda-García, Lucía González-Pinto, Andrea García-Pose, Paula Guijarro-Sánchez, Isaac Alonso-García, Emilio Lence, Concepción González-Bello, Antonio Oliver, Jorge Arca-Suárez, Bartolome Moya, Germán Bou, Alejandro Beceiro   +15 more
doaj   +1 more source

A review of antibiotic safety in pregnancy—2025 update

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen, Victoria Madonia, Christopher M. Bland, Kayla R. Stover, Lea S. Eiland, Julia Keating, Madeline Lemmon, P. Brandon Bookstaver, as part of the Southeastern Research Group Endeavor (SERGE‐45) research network   +8 more
wiley   +1 more source

Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant \u3ci\u3eAcinetobacter baumannii\u3c/i\u3e Infections

, 2023
OBJECTIVE: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant DATA SOURCES: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam ...
Kale-Pradhan, Pramodini B, Matlob, Andrew, August, Benjamin A   +2 more
core   +1 more source

Efficacy and safety of antibiotics in the treatment of multidrug-resistant Acinetobacter baumannii infections: A systematic review and Bayesian network meta-analysis

Journal of Global Antimicrobial Resistance
: Objectives: This study aims to compare the efficacy and safety of antimicrobial regimens for multidrug-resistant Acinetobacter baumannii (MDR A. baumannii) infections using a Bayesian network meta-analysis (NMA).
Binh Van Tran, Phi Yen Huynh, Tu Tuan Tran, Bao Bui Hoang, Ka-Wai Tam   +4 more
doaj   +1 more source

Synthesis and Evaluation of Carbapenem/Metallo‐β‐Lactamase Inhibitor Conjugates

ChemMedChem, Volume 19, Issue 21, November 4, 2024.
We report the synthesis and evaluation of molecular conjugates that combine a carbapenem antibiotic (meropenem or ertapenem) with a recently reported indole carboxylate scaffold. These hybrids are potent inhibitors of metallo‐β‐lactamases including the clinically relevant NDM‐1 and IMP‐1 enzymes.
Mei‐Ling Gao, Ioli Kotsogianni, Foteini Skoulikopoulou, Nora C. Brüchle, Paolo Innocenti, Nathaniel I. Martin   +5 more
wiley   +1 more source

Microbiological eradication of XDR Acinetobacter baumannii intra-abdominal infection using sulbactam-durobactam: clinical and microbiological outcomes amidst irreversible host comorbidities

Frontiers in Medicine
BackgroundThe management of extensively drug-resistant (XDR) Acinetobacter baumannii (CRAB) in deep-seated infections remains a critical challenge, particularly when compounded by severe host comorbidities.Case presentationWe report the case of a 63-year-
Lei Yu, Jieli He, Waiming Chan, Waiming Chan, Shan Zou, Qingshan Zhou, Jun Jin   +6 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Future Microbiology
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older.
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye   +4 more
openaire   +2 more sources